Pre- and post-TRALI mitigation factors: Number of TRALI cases per product distributed/transfused. The plateletpheresis product risk reduction shows pre- and postimplementation of products from males or nulligravida or HLA-antibody-negative parous females per New York Blood Center data.⁸  The current risk for the RBC product is per New York Blood Center data. The arrow shows potential risk reduction with use of an experimental filter.^2,8  The left-most plasma product risk reduction shows pre- and postimplementation of products from males or nulligravida females per New York Blood Center data.⁸  The right-most plasma product risk reduction shows pre- and postimplementation of solvent detergent products per French Agency for the Safety of Health Products data.³